期刊文献+

人α-突触核蛋白基因慢病毒稳定转染PC12细胞系的建立及其凋亡检测 被引量:2

Stably expression human α-synuclein gene in PC12 cells by lentivirus and apoptosis detection
原文传递
导出
摘要 目的构建及鉴定人野生型和突变型α-突触核蛋白(SNCA和SNCAmu)基因慢病毒表达载体,并观察在体外大鼠嗜铬细胞瘤细胞中的表达。方法在引物合成后采用PCR技术扩增目的基因,并将基因克隆到慢病毒载体表达质粒[pGC—FU,含绿色荧光蛋白(GFP)基因]中,构建SNCA基因慢病毒载体表达质粒(pGC—FU—SNCA—GFP)和SNCAmu基因慢病毒载体表达质粒(pGC—FU—SNCAmu—GFP),通过酶切、测序验证后,将pGC—FU—SNCA—GFP、pGC—FU—SNCAmu—GFP质粒和包装质粒pHelper1.0、pHelper2.0共同转染大鼠嗜铬细胞瘤细胞(PCI2细胞),获得稳定转染。结果通过检测标签蛋白GFP和目的蛋白,进一步验证pGC—FU—SNCA—GFP和pGC—FU—SNCAmu—GFP在靶细胞中的表达。通过噻唑蓝比色法检测稳定转染后细胞凋亡水平,稳定表达SNCA组(OE组)、SNCAmu组(OEm组)、不加慢病毒质粒的空白对照组(CON组)和加pGC—FU—GFP空载体对照组(NC组)共4组细胞,病毒转染后不同时间(1、2、3、4、5d)细胞增殖变缓(F=4.534、196.285、411.829、1282.049、3135.559,均P〈0.05)。碘化丙锭单染法检测细胞周期,CON组、NC组、OE组和OEm组G1期、G2期和M期细胞百分比差异有统计学意义(F=885.79、45.03、207.11,均P〈0.05),其中G1期细胞百分比(%)较高(CON组:59.10±0.35、NC组:68.24±0.60、OE组:71.73±0.11、OEm组:74.66±0.35)。结论人SNCA和SNCAmu基因转染到PC12细胞中,成功建立稳定表达的细胞系,并且对细胞凋亡水平和细胞周期有一定程度的改变。 Objective Construction and identification of wild-type and mutant human α-synuclein (SNCA) gene lentiviral expression vector, and its stable transfection into the rat pheochromocytoma cells. Methods The genes were synthesized with particular primer, amplified by PCR and cloned into the lentiviral vector expression plasmid pGC-FU ( with green fluorescent protein ( GFP ) gene ) to construct a lentiviral vector expression plasmid pGC-FU-SNCA-GFP and pGC-FU-SNCA-GFP. After digestion and sequencing, pGC-FU-SNCA-GFP, pGC-FU-SNCA-GFP plasmid and packaging plasmid pHelperl. 0, pHelper2.0 were co-transfected into rat pheochromocytoma cells (PC12 cells). A stable transfection was established in the PC12 cells. Results By detecting the level of tagged protein of GFP and the target protein, the pGC-FU-SNCA-GFP and pGC-FU-SNCA-GFP expression in target cells was verified. MTT assay was employed to detect cell apoptosis in lentiviral pGC-FU-SNCA-GFP transfected group, lentiviral pGC-FU- SNCAmu-GFP transfected group (experimental groups), without virus group (control group ) and empty vector group(total four groups cells). After transfection, at different timepoints (1, 2, 3, 4 and 5 d) the proliferation of cells was slowed (the F value was 4. 534, 196. 285, 411. 829, 1282. 049, 3135. 559, all P 〈 0. 05 ). PI single staining was used to examine the cell cycle. The percentages of G1 phase, G2 phase, M phase cells were all statistically significant ( the F value was 885.79, 45.03,207. 11, all P 〈 0. 05 ). The percentage of G1 phase cells in the four groups cells increased significantly (CON group :59, 10 ± 0. 35, NC group:68.24 ±0.60, OE group:71.73 ±0.11, OE group:74.66±0.35). Conclusion This study constructs a foundation for further investigation on the basic function of SNCA and apoptosis related diseases.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2011年第9期602-607,共6页 Chinese Journal of Neurology
基金 国家自然科学基金资助项目(30270493) 上海市引进海外高层次留学人员专项基金资助项目(20040115) 上海自然科学基金资助项目(01ZB14050) 上海市科学技术发展基金重点资助项目(024119037) 上海交通大学优秀中青年科研基金资助项目(2005-3-8)
关键词 Α突触核蛋白 慢病毒属 转染 PC12细胞 细胞凋亡 alpha-Synuclein Lentivirus Transfection PC12 cells Apoptosis
  • 相关文献

参考文献14

  • 1Dauer W, Przedborski S. Parkinson' s disease: mechanisms and models. Neuron, 2003, 39: 889-909.
  • 2Csoti I, Fornadi F. Differential diagnosis of atypical Parkinsonian syndromes. Ideggyogy Sz, 2010, 63:77-86.
  • 3George JM. The synucleins. Genome Biol, 2002, 3 : 1-6.
  • 4Senior SL, Ninkina N, Deacon R, et al. Increased striatal dopamine release and hyperdopaminergic-like bahaviour in mice lacking both alpha-synucelin and gamma-synucelin. Eur J Neurosci, 2008, 27: 947-957.
  • 5Halliday GM, McCann H. The progression of pathology in Parkinson' s disease. Ann N Y Acad Sci, 2010,1184: 188-195.
  • 6Cockrell AS, Kafri T. Gene delivery by lenlivirus vectors. Mol Biotechnol, 2007. 36: 184-204.
  • 7Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006, 1:241-245.
  • 8Schulz JB. Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat Disord, 2007, 13 Suppl 3 :S306-308.
  • 9hnai Y, Takahashi R. Frontier researches for the development of molecular-targeted therapies for familial Parkinson disease. Brain Nerve, 2009, 61: 903-913.
  • 10Takeda A, Sugeno N, Hasegawa T, et al. Cellular pathophysiology of Parkinson's disease. Rinsho Shinkeigaku, 2008, 48:984-985.

二级参考文献30

  • 1Wang CK Chen CM Chang CY Chang KH Chen IC Li ML Lee-Chen G J Wu YR.alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease[J].中国生物学文摘,2006,20(8):17-17. 被引量:2
  • 2钱进军,程言博,刘春风,胡伟东.人SNCA及其致病突变基因的逆转录病毒pEGZ/MCSHA载体的构建[J].中国临床神经科学,2006,14(6):561-565. 被引量:3
  • 3Terman A, Gustafsson B, Brunk UT. Autophagy, organelles and ageing. J Pathol, 2007, 211: 134-143.
  • 4Kuma A, Hatano M, Matsui M, et al. The role of autophagy during the early neonatal starvation period. Nature, 2004, 432: 1032-1036.
  • 5Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson' s disease. Histol Histopathol, 1997, 12: 25-31.
  • 6Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 2006, 443: 780-786.
  • 7Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci, 2001, 21 : 9549-9560.
  • 8Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature, 1997, 388: 839-840.
  • 9Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 2000, 287: 1265-1269.
  • 10Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 2000, 290 : 985-989.

共引文献12

同被引文献17

  • 1Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain : clinical, prognostic, and genetic survey. Eur J Neurol, 2011,18 : 1203-1211.
  • 2Rafiq M, Sharrack N, Shaw P J, et al. A neurological rarity not to be missed : cerebrotendinous xanthomatosis. Pract Neurol, 2011, 11:296-300.
  • 3Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci,2006.27: 143-149.
  • 4Moghadasian MH. Cerebrotendinous xanthomatosis : clinical course, genotypes and metabolic backgrounds. Clin Invest Med, 2004,27 : 42-50.
  • 5Fillppi J, Irarr6zaval S, Peredo P, et al. Cerebrotendinous xanthomatosis report of one case. Rev M6d Chile,2009,137: 815- 820.
  • 6Okuma H, Kitagawa Y, Tokuoka K, et al. Cerebrotendinous Xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med ,2007,46 : 1259-1261.
  • 7Grandas F, Martin-Moro M, Garcia-Munozguren S, et al. Early- onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord,2002,17 : 1396-1397.
  • 8Pilo B, de Blas G, Sobrido M J, et al. Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve, 2011,43 : 531- 536.
  • 9Pilo-de-la-Fuente B, Sobrido MJ, Giros M, et al. Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. Neurologia,2011,26 :397-404.
  • 10Naqi S, Bouchriha M, Sehai R, et al. Imaging of cerehrotendinous xanthomatosis. J Radio1,2006,87 : 1883-1886.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部